StockpollyBeta
Get App
Popularity #1,541
PRME · NASDAQ · Biotechnology

Prime Medicine (PRME)

Develops Prime Editing therapies for liver, lung, and partnered cell-therapy programs.

$3.50
After hours−0.04 (−1.27%)
At close$3.55(+11.13%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue001002111111
Cost of revenue0010000244020
Gross profit00−10021−1−431−11
516848565446545311495044
Research & development414138434034414144353433
101311131412131311151711
General & administrative101311131412131311151711
Other expenses014−10000−2−440−20
Operating income−51−68−48−56−54−44−52−53−54−49−51−43
123022113321
Interest income001112111111
Other non-operating income0−14−30−2−2−1−1−3−3−2−1
Income before tax−51−66−46−55−53−42−52−53−51−46−49−42
Income tax expense000000000000
Net income from continuing operations−51−66−46−55−53−42−52−53−51−46−49−42
Net income−51−66−46−55−53−42−52−53−51−46−49−42
EPS, basic−$0.55−$0.67−$0.44−$0.46−$0.44−$0.36−$0.40−$0.41−$0.32−$0.26−$0.28−$0.24
EPS, diluted−$0.55−$0.67−$0.44−$0.46−$0.44−$0.36−$0.40−$0.41−$0.32−$0.26−$0.28−$0.24
Weighted average shares, basic9297104119120119131129161149177177
Weighted average shares, diluted9297104119120119131129161149177177
EBITDA−50−53−44−54−51−41−50−51−49−44−47−40
Depreciation & amortization111222222222
EBIT−51−55−46−55−53−42−52−53−51−46−49−42